s'authentifier
version française rss feed
Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
Ploussard G., Salomon L., Xylinas E., Allory Y., Vordos D., Hoznek A., Abbou C.-C., De La Taille A.
Journal of Urology The 183, 2 (2010) 539-44 - http://www.hal.inserm.fr/inserm-00453763/en/
(20006888)
Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
Guillaume Ploussard1, 2, 3, Laurent Salomon1, 2, 3, Evanguelos Xylinas1, 2, 3, Yves Allory1, 2, 3, Dimitri Vordos1, 2, 3, Andras Hoznek1, 2, 3, Claude-Clément Abbou1, 2, 3, Alexandre De La Taille () 1, 2, 3
1 :  Institut Mondor de Recherche Biomédicale
INSERM : U955 – Université Paris XII Val de Marne – IFR10
France
2 :  Service d'urologie
AP-HP – Hôpital Henri Mondor – Université Paris XII Val de Marne
51, av du Maréchal de Tassigny, Créteil
France
3 :  Service d'anatomie pathologique
AP-HP – Hôpital Henri Mondor – Université Paris XII Val de Marne
Créteil
France
PURPOSE: We compared the pathological findings and prostate specific antigen outcome after radical prostatectomy in men eligible for active surveillance according to 3 biopsy inclusion criteria. MATERIALS AND METHODS: The study population included 177 men eligible for active surveillance who fulfilled clinicobiological criteria and biopsy criteria as group 1-less than 3 positive cores and less than 3 mm total tumor length, group 2-less than 3 positive cores with cancer involvement of less than 50% in any core and group 3-less than 33% of positive cores. Prostate specific antigen density cutoffs were also studied in these groups. Pathological findings on radical prostatectomy specimens and biochemical recurrence-free survival were studied. Median followup after radical prostatectomy was 34 months. RESULTS: A majority of Gleason score 6 disease was observed in group 1 (51.7%) whereas a majority of Gleason score 7 or greater disease was reported in groups 2 (53.6%) and 3 (55.4%). Extracapsular extension was noted in 17.5% of radical prostatectomy specimens in group 3 vs 11.2% in group 1 (p = 0.175). The risk of overall unfavorable disease (defined as pT3-4 stage and/or Gleason score 8 or greater) was significantly higher in men with cancer involvement of 3 mm or greater on initial biopsy (27.3% vs 13.5%, respectively, p = 0.023). The 3-year biochemical recurrence-free survival rate was 94.0% and was not affected by the 3 active surveillance definitions. CONCLUSIONS: Even with the use of a 21-core biopsy protocol the rate of unfavorable disease in radical prostatectomy specimens remains increased in men eligible for active surveillance. Patients must be informed of this risk of misclassification which ranges from 20% to 28% in men who fulfill the less stringent biopsy criteria.
Sciences du Vivant/Biochimie, Biologie Moléculaire
Anglais
1527-3792

Inserm U955, équipe 7

Articles dans des revues avec comité de lecture
10.1016/j.juro.2009.10.009
Journal of Urology The (J Urol)
Publisher Elsevier;Wolters Kluwer - Lippincott Williams & Wilkins
ISSN 0022-5347 
internationale
02/2010
14/12/2009
183
2
539-44

prostate cancer – radical prostatectomy – active surveillance – low risk
Liste des fichiers attachés à ce document : 
DOC
AS.JUrol.R1.doc(83 KB)
Figure1.doc(25 KB)
Table1.R1.doc(30.5 KB)
Table2.R1.doc(57 KB)
Table3.R1.doc(67 KB)
PDF
AS.JUrol.R1.pdf(156 KB)
Figure1.pdf(35 KB)
Table1.R1.pdf(34.1 KB)
Table2.R1.pdf(86.9 KB)
Table3.R1.pdf(88.9 KB)

tous les articles de la base du CCSd...